Viking Therapeutics (1VT) Price & Analysis

Compare

71 Followers

1VT Stock Chart & Stats

€29.90

-€0.26(-0.65%)

At close: Jan 08 4:00 PM EST

€29.90

-€0.26(-0.65%)

Day’s Range― - ―

52-Week Range€16.40 - €47.09

Previous CloseN/A

Volume0.00

Average Volume (3M)384.00

Market Cap

€3.40B

Enterprise Value€2.85B

Total Cash (Recent Filing)€714.57M

Total Debt (Recent Filing)€755.00K

Price to Earnings (P/E)―

Beta2.09

Next Earnings

Feb 11, 2026

EPS Estimate

-0.77

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.69

Shares Outstanding113,036,350

10 Day Avg. Volume207

30 Day Avg. Volume384

Financial Highlights & Ratios

PEG Ratio-3.63

Price to Book (P/B)4.98

Price to Sales (P/S)0.00

P/FCF Ratio-49.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€83.05

Price Target Upside177.76% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessEli Lilly's Phase 3 ATTAIN-MAINTAIN trial provides external validation for Viking's oral VK2735 program, supporting its long-term weight maintenance strategy.

Market EnthusiasmThe rapid pace of enrollment is a reflection of enthusiasm for VK2735.

Strategic AdvantagesViking's plan to transition patients from subcutaneous to oral formulations of the same molecule, VK2735, is seen as a key differentiator that supports a seamless and predictable transition.

Bears Say

Viking Therapeutics News

These 3 Biotech Stocks Can Triple from Current Levels, Say Five-Star Analysts – 12/19/2025

If you’re looking for investment ideas right now, several top-rated Wall Street analysts (each with five-star ratings) believe...

21h ago

ANAB

LBRX

H.C. Wainwright says Lilly’s topline results de-risk Viking oral VK2735 program

H.C. Wainwright notes that this morning, Eli Lilly (LLY) announced positive topline results from the Phase 3 ATTAIN-MAINTAIN...

2d ago

LLY

VKTX

Crypto Currents: Bitcoin settlement volume flips Visa

Wall Street maintains a bullish outlook on Strategy despite recent volatility, while bitcoin miners increasingly diversify into artificial...

10d ago

Viking Therapeutics call volume above normal and directionally bullish

Bullish option flow detected in Viking Therapeutics (VKTX) with 7,276 calls trading, 1.4x expected, and implied vol increasing...

29d ago

VKTX

Viking Therapeutics: External Validation and Same-Molecule Strategy De-Risk Obesity Program, Supporting Buy Rating

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Viking Therapeutics. The associated price target...

2d ago

VKTX

Strong Enrollment and Promising Strategy Propel Viking Therapeutics to ‘Buy’ Rating

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Viking Therapeutics. The associated price target...

1M ago

VKTX

Promising Potential of Viking Therapeutics’ VK2735 Justifies Buy Rating

William Blair analyst Andy Hsieh has maintained their bullish stance on VKTX stock, giving a Buy rating on...

1M ago

VKTX

Viking Therapeutics completes patient enrollment in VANQUISH-1 clinical trial

Viking Therapeutics (VKTX) announced the completion of patient enrollment in its Phase 3 VANQUISH-1 clinical trial of subcutaneous...

1M ago

VKTX

Viking Therapeutics price target raised to $107 from $106 at Canaccord

Canaccord raised the firm’s price target on Viking Therapeutics (VKTX) to $107 from $106 and keeps a Buy...

1M ago

MTSR

VKTX

Viking Therapeutics Stock (VKTX) Jumps on Obesity Drug. Next Big Pharma Target?

Shares of biopharma company Viking Therapeutics ($VKTX) rose as high as 5% during the first hour of trading...

1M ago

NVO

PFE

Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

Traders will find all of the hottest stock market stories worth reading today in the TipRanks daily wrap-up. ...

1M ago

Viking Therapeutics’ VK2735: A Promising Step Forward in Metabolic Disease Treatment Justifying a Buy Rating

Maxim Group analyst Naz Rahman has reiterated their bullish stance on VKTX stock, giving a Buy rating yesterday....

1M ago

VKTX

Viking Therapeutics’ VK2735 Trials and Strategic Positioning Drive Buy Rating

William Blair analyst Andy Hsieh has maintained their bullish stance on VKTX stock, giving a Buy rating today....

1M ago

VKTX

Promising Potential of Viking Therapeutics’ VK2735: A Buy Rating Justified by Efficacy in Weight Loss and Metabolic Health

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Viking Therapeutics and keeping the price target...

1M ago

VKTX

1VT FAQ

What was Viking Therapeutics’s price range in the past 12 months?

Viking Therapeutics lowest stock price was €16.40 and its highest was €47.09 in the past 12 months.

What is Viking Therapeutics’s market cap?

Viking Therapeutics’s market cap is €3.40B.

When is Viking Therapeutics’s upcoming earnings report date?

Viking Therapeutics’s upcoming earnings report date is Feb 11, 2026 which is in 53 days.

How were Viking Therapeutics’s earnings last quarter?

Viking Therapeutics released its earnings results on Oct 22, 2025. The company reported -€0.692 earnings per share for the quarter, missing the consensus estimate of -€0.606 by -€0.085.

Is Viking Therapeutics overvalued?

According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Viking Therapeutics pay dividends?

Viking Therapeutics does not currently pay dividends.

What is Viking Therapeutics’s EPS estimate?

Viking Therapeutics’s EPS estimate is -0.77.

How many shares outstanding does Viking Therapeutics have?

Viking Therapeutics has 113,036,350 shares outstanding.

What happened to Viking Therapeutics’s price movement after its last earnings report?

Viking Therapeutics reported an EPS of -€0.692 in its last earnings report, missing expectations of -€0.606. Following the earnings report the stock price went up 7.51%.

Which hedge fund is a major shareholder of Viking Therapeutics?

Currently, no hedge funds are holding shares in DE:1VT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Viking Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-29.23%

Trailing 12-Months

Asset Growth

-21.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Viking Therapeutics

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics (1VT) Earnings & Revenues

Historic Earnings Reports

1VT Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant progress in clinical trials for obesity treatments, with positive Phase II results and the initiation of Phase III trials. However, the financial report showed increased losses and decreased cash reserves.View all DE:1VT earnings summaries

1VT Stock 12 Month Forecast

Average Price Target

€83.05

▲(177.76% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"€21","64":"€64","107":"€107","42.5":"€42.5","85.5":"€85.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":106.7255,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€106.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83.04951508,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€83.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":59.76628,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€59.77</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,42.5,64,85.5,107],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.6,38.30196153846154,44.00392307692307,49.70588461538461,55.40784615384615,61.10980769230769,66.81176923076922,72.51373076923076,78.21569230769231,83.91765384615384,89.61961538461537,95.32157692307692,101.02353846153844,{"y":106.7255,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.6,36.48073192923077,40.36146385846154,44.24219578769231,48.12292771692308,52.00365964615385,55.88439157538462,59.76512350461539,63.64585543384616,67.52658736307693,71.4073192923077,75.28805122153847,79.16878315076923,{"y":83.04951508,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.6,34.68971384615385,36.77942769230769,38.86914153846154,40.95885538461539,43.04856923076923,45.13828307692308,47.22799692307693,49.31771076923077,51.40742461538461,53.49713846153846,55.58685230769231,57.67656615384615,{"y":59.76628,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":66.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.56,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.24,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.03,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.005,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.495,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >